Journal of Postgraduate Medicine, Education and Research

Register      Login

VOLUME 54 , ISSUE 2 ( April-June, 2020 ) > List of Articles

Clinicopathological Conference Report

Non-Hodgkin's Lymphoma: What Matters Tumor Type or Burden?

Dr Balamurugan Thirunavukkarasu, Dr Ashish Behera, Dr Nidhi Prabhakar, Dr Divya Aggarwal, Dr Deepesh Lad, Prof Rakesh Kochar

Citation Information : Thirunavukkarasu DB, Behera DA, Prabhakar DN, Aggarwal DD, Lad DD, Kochar PR. Non-Hodgkin's Lymphoma: What Matters Tumor Type or Burden?. J Postgrad Med Edu Res 2020; 54 (2):69-76.

DOI: 10.5005/jp-journals-10028-1360

License: CC BY-NC 4.0

Published Online: 11-10-2020

Copyright Statement:  Copyright © 2020; The Author(s).


  1. Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol 2019;94(5):604–616. DOI: 10.1002/ajh.25460.
  2. Melchardt T, Troppan K, Weiss L, et al. A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and β2-microglobulin. Br J Haematol 2015;168(2):239–245. DOI: 10.1111/bjh.13116.
  3. Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology 2018;50(1):74–87. DOI: 10.1016/j.pathol.2017.09.006.
  4. Sehn LH, Berry B, Chhanabhai M, et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109(5):1857–1861. DOI: 10.1182/blood-2006-08-038257.
  5. Kubo K, Kimura N, Mabe K, et al. Acute liver failure associated with diffuse large B-cell lymphoma: an autopsy case report. Clin J Gastroenterol 2020. DOI: 10.1007/s12328-019-01091-6.
  6. Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol 2014;66(9):2613–2620. DOI: 10.1002/art.38690.
  7. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016;315(8):801–810. DOI: 10.1001/jama.2016.0287.
  8. Kapuria D, Strasser K, Qasem A. Diffuse large B-cell lymphoma causing acute liver failure: a rare case of survival. BMJ Case Rep 2015;2015(1). DOI: 10.1136/bcr-2015-209328.
  9. Shibata J, Kurahashi S, Naito T, et al. Diffuse large B cell lymphoma primarily presenting as acute liver failure in a surviving patient. J Community Hosp Intern Med Perspect 2019;9(2):135–139. DOI: 10.1080/20009666.2019.1583535.
  10. Tsuyama N, Sakata S, Baba S, et al. BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation. Blood 2017;130(4):489–500. DOI: 10.1182/blood-2016-12-759621.
  11. Li L, Li Y, Que X, et al. Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: a systematic review and meta-analysis. Sci Rep 2018;8(1):6267. DOI: 10.1038/s41598-018-24631-5.
  12. Tang YL, Zhou Y, Cheng LL, et al. BCL2/ki-67 index predict survival in germinal center B-cell-like diffuse large B-cell lymphoma. Oncol Lett 2017;14(3):3767–3773. DOI: 10.3892/ol.2017.6577.
  13. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403(6769):503–511. DOI: 10.1038/35000501.
  14. Coutinho R, Clear AJ, Owen A, et al. Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large b-cell lymphoma: Implications for therapeutic strategies. Clin Cancer Res 2013;19(24):6686–6695. DOI: 10.1158/1078-0432.CCR-13- 1482.
  15. Dwivedi A, Mehta A, Solanki P. Evaluation of immunohistochemical subtypes in diffuse large B-cell lymphoma and its impact on survival. Indian J Pathol Microbiol 2015;58(4):453–458. DOI: 10.4103/0377-4929.168886.
  16. Gutiérrez-García G, Cardesa-Salzmann T, Climent F, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood 2011;117(18):4836–4843. DOI: 10.1182/blood-2010-12-322362.
  17. Hu S, Xu-Monette ZY, Wu L, et al. MYC/BCL2 protein co-expression defines a unique subset of aggressive lymphoma and contributes to the inferior prognosis of activated B-cell subtype of diffuse large B-cell lymphoma: a report from the international DLBCL rituximab-CHOP consortium program s. Clin Lymphoma, Myeloma Leuk 2013;13(20):S382–S383. DOI: 10.1016/j.clml.2013.07.095.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.